|
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
RECRUITINGN/ASponsored by University of Pennsylvania
Actively Recruiting
PhaseN/A
SponsorUniversity of Pennsylvania
Started2023-03-10
Est. completion2025-12
Eligibility
Age18 Years – 89 Years
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →
NCT05631223
Summary
This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).
Eligibility
Age: 18 Years – 89 YearsHealthy volunteers accepted
Inclusion Criteria: * Population: Patients with Psoriatic Arthritis * Age 18-89. * Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10). * Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit). * Meet CASPAR criteria. * Provision of signed and dated informed consent form. * Willingness to comply with all study procedures and availability for duration of the study. * Has access to a mobile phone or other mobile device. Exclusion Criteria: * Inability to provide informed consent. * Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks. * PsAID score ≤4
Conditions1
Psoriatic Arthritis
Locations2 sites
Pennsylvania
1 siteUniversity Of Pennsylvania
Philadelphia, Pennsylvania, 19104
Sarah GillespieSarah.Hopkins@Pennmedicine.upenn.edu
Utah
1 siteTrial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity of Pennsylvania
Started2023-03-10
Est. completion2025-12
Eligibility
Age18 Years – 89 Years
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →
NCT05631223